RapidBac™Vet Combating Antimicrobial Resistance in Veterinary Care

AZUSA, CA, USA, 2019-Aug-29 — /EPR Network/ — Antibiotic resistance is a growing concern in today’s medical and veterinary fields. Advances in veterinary medicine are important for providing better and faster solutions to avoid empirical use of antimicrobial therapy. Today, Silver Lake Research Corporation is taking urine cultures out of the laboratories and into the clinics with RapidBac^™Vet. RapidBac™Vet is the first rapid immunoassay urine test that provides you with the most affordable, validated[i] in-house screening tool for bacteriuria. RapidBac™Vet indicates whether the bacteria is Gram-positive or Gram-negative so you can immediately determine the need for antibiotics.

Cost can be a major barrier to culture and sensitivity testing for pet owners. RapidBac™Vet can be incorporated into the urine diagnostic work-up to offer patients an inexpensive option in determining immediate treatment, thus delivering antimicrobial treatment judiciously. Benefits of RapidBac™Vet include: results appearing in less than twenty minutes, costing one-third as much as urine culture and not requiring any instrumentation or refrigeration. RapidBac™Vet expands a clinic’s in-house bacteria testing capability and allows clinical teams to test and treat in the same visit.

RapidBac™Vet can be used as an inexpensive alternative to culture when it comes to:

• Point-of-care treatment decisions for patients who are suspected of having bacteriuria
• Re-checking patients who have been on antibiotics
• Screening for bacteriuria in diabetic and renal disease patients or any patients with dilute urine
• Cats who suffer from feline idiopathic cystitis to rule out bacteriuria

RapidBac^™Vet requires minimal training, can be stored at room temperature and has an 18 month shelf-life. To learn more about RapidBac^™Vet, visit www.rapidbacvet.com or call 888.438.1942.

About Silver Lake Research Corporation

Silver Lake Research Corporation develops unique antibodies and patented antibody-based diagnostic products for commercial partners as well as its own portfolio. We bring leading edge design, development, and manufacturing capabilities together in one place at our Southern California facilities.

[i] Jacob ME et al. AJVR 2016; 77(2): 162-6.